Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Open Access
- 25 March 2018
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 6 (2), 1-7
- https://doi.org/10.14218/jcth.2017.00050
Abstract
Non-alcoholic fatty liver disease (NAFLD), the most common cause of liver disease, affects approximately 75 to 100 million Americans. Patients with concurrent NAFLD and type 2 diabetes mellitus have a higher risk of progressing to advanced fibrosis and non-alcoholic steatohepatitis compared to non-diabetics. Lifestyle modifications, including weight loss, remain the mainstay of treatment for NAFLD, as there are no medications currently indicated for this disease state. Anti-diabetic pharmacologic therapies aimed at improving insulin sensitivity and decreasing insulin production have been studied to determine their potential role in slowing the progression of NAFLD. In this review, we focus on the evidence surrounding anti-diabetic medications and their ability to improve disease progression in patients with NAFLD.Keywords
This publication has 71 references indexed in Scilit:
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysisJournal of Hepatology, 2011
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2010
- Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver diseaseHepatology International, 2010
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathwayJournal of Hepatology, 2010
- Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trialScandinavian Journal of Gastroenterology, 2009
- Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat DietThe Journal of pharmacology and experimental therapeutics, 2008
- Spontaneous hepatocarcinogenesis in farnesoid X receptor-null miceCarcinogenesis: Integrative Cancer Research, 2006